Clinical Trial Update: Neoadjuvant Dalpiciclib Plus Letrozole for HR+/HER2- Breast Cancer [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial update evaluating neoadjuvant dalpiciclib plus letrozole for HR+/HER2- breast cancer is reported, with current status unknown.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Dalpiciclib (dalpiciclib)
• Letrozole (letrozole)

Snippet

Sponsor: The Affiliated Hospital of Qingdao University | Conditions: Breast Cancer | Phase 2 | Status: UNKNOWN